We are live on
!
Find out more
Acadia Pharmaceuticals
ACAD
ACAD
212 hedge funds and large institutions have $3.07B invested in Acadia Pharmaceuticals in 2016 Q1 according to their latest regulatory filings, with 38 funds opening new positions, 94 increasing their positions, 62 reducing their positions, and 39 closing their positions.
New
Increased
Maintained
Reduced
Closed
52% more repeat investments, than reductions
Existing positions increased: 94 | Existing positions reduced: 62
0% more funds holding in top 10
Funds holding in top 10: 4 → 4 (0)
1% less funds holding
Funds holding: 214 → 212 (-2)
3% less first-time investments, than exits
New positions opened: 38 | Existing positions closed: 39
11% less call options, than puts
Call options by funds: $88.5M | Put options by funds: $99.7M
11% less capital invested
Capital invested by funds: $3.47B → $3.07B (-$398M)
Holders
212
Holders Change
-2
Holders Change %
-0.93%
% of All Funds
5.65%
Holding in Top 10
4
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.11%
New
38
Increased
94
Reduced
62
Closed
39
Calls
$88.5M
Puts
$99.7M
Net Calls
-$11.2M
Net Calls Change
+$1.64M
Top Buyers
| 1 |
BBA
Baker Bros. Advisors
New York
|
+$81.4M |
| 2 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$52.2M |
| 3 |
Point72 Asset Management
Stamford,
Connecticut
|
+$41.8M |
| 4 |
Fidelity Investments
Boston,
Massachusetts
|
+$38.2M |
| 5 |
O
OrbiMed
New York
|
+$30.6M |
Top Sellers
| 1 |
Westfield Capital Management
Boston,
Massachusetts
|
-$32M |
| 2 |
AllianceBernstein
Nashville,
Tennessee
|
-$29.6M |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$23.3M |
| 4 |
BAMCO Inc
New York
|
-$22.7M |
| 5 |
VAM
Visium Asset Management
New York
|
-$17.8M |
